370 related articles for article (PubMed ID: 21378357)
21. Significance of alpha-fetoprotein and des-gamma-carboxy prothrombin in patients with hepatocellular carcinoma undergoing hepatectomy.
Yamamoto K; Imamura H; Matsuyama Y; Hasegawa K; Beck Y; Sugawara Y; Makuuchi M; Kokudo N
Ann Surg Oncol; 2009 Oct; 16(10):2795-804. PubMed ID: 19669841
[TBL] [Abstract][Full Text] [Related]
22. [Significance of Golgi glycoprotein 73, a new tumor marker in diagnosis of hepatocellular carcinoma: a primary study].
Mao YL; Yang HY; Xu HF; Sang XT; Lu X; Yang ZY; Zhang JC; Zhong SX; Huang JF; Zhang HB
Zhonghua Yi Xue Za Zhi; 2008 Apr; 88(14):948-51. PubMed ID: 18756964
[TBL] [Abstract][Full Text] [Related]
23. [Optimal cut-off value of PIVKA-II for diagnosis of hepatocellular carcinoma--using ROC curve].
Kim MJ; Bae KW; Seo PJ; Jeong IK; Kim JH; Lee BH; Bang KT; Kim DW; Song IH
Korean J Hepatol; 2006 Sep; 12(3):404-11. PubMed ID: 16998292
[TBL] [Abstract][Full Text] [Related]
24. Serum levels of des-gamma-carboxy prothrombin measured using the revised enzyme immunoassay kit with increased sensitivity in relation to clinicopathologic features of solitary hepatocellular carcinoma.
Okuda H; Nakanishi T; Takatsu K; Saito A; Hayashi N; Takasaki K; Takenami K; Yamamoto M; Nakano M
Cancer; 2000 Feb; 88(3):544-9. PubMed ID: 10649245
[TBL] [Abstract][Full Text] [Related]
25. The predictive ability of serum alpha-fetoprotein for hepatocellular carcinoma is linked with the characteristics of the target population at surveillance.
Huo TI; Hsia CY; Chu CJ; Huang YH; Lui WY; Wu JC; Lee PC; Chi CW; Lee SD
J Surg Oncol; 2007 Jun; 95(8):645-51. PubMed ID: 17530668
[TBL] [Abstract][Full Text] [Related]
26. Utility of alpha-fetoprotein (AFP) in the screening of patients with virus-related chronic liver disease: does different viral etiology influence AFP levels in HCC? A study in 350 western patients.
Cedrone A; Covino M; Caturelli E; Pompili M; Lorenzelli G; Villani MR; Valle D; Sperandeo M; Rapaccini GL; Gasbarrini G
Hepatogastroenterology; 2000; 47(36):1654-8. PubMed ID: 11149026
[TBL] [Abstract][Full Text] [Related]
27. The effectiveness of serum alpha-fetoprotein level in anti-HCV positive patients for screening hepatocellular carcinoma.
Peng YC; Chan CS; Chen GH
Hepatogastroenterology; 1999; 46(30):3208-11. PubMed ID: 10626187
[TBL] [Abstract][Full Text] [Related]
28. Serum VEGF as a tumor marker in patients with HCV-related liver cirrhosis and hepatocellular carcinoma.
Mukozu T; Nagai H; Matsui D; Kanekawa T; Sumino Y
Anticancer Res; 2013 Mar; 33(3):1013-21. PubMed ID: 23482775
[TBL] [Abstract][Full Text] [Related]
29. Combined serum hepatoma-specific alpha-fetoprotein and circulating alpha-fetoprotein-mRNA in diagnosis of hepatocellular carcinoma.
Wu W; Yao DF; Yuan YM; Fan JW; Lu XF; Li XH; Qiu LW; Zong L; Wu XH
Hepatobiliary Pancreat Dis Int; 2006 Nov; 5(4):538-44. PubMed ID: 17085339
[TBL] [Abstract][Full Text] [Related]
30. Combined assessment of TGF-beta-1 and alpha-fetoprotein values improves specificity in the diagnosis of hepatocellular carcinoma and other chronic liver diseases in Malaysia.
Yasmin Anum MY; Looi ML; Nor Aini AH; Merican I; Wahidah A; Mohd Radzi AH; Nor Azizah A; Othman NH
Med J Malaysia; 2009 Sep; 64(3):223-7. PubMed ID: 20527273
[TBL] [Abstract][Full Text] [Related]
31. Proteomics of hepatocellular carcinoma: serum vimentin as a surrogate marker for small tumors (Sun S; Poon RT; Lee NP; Yeung C; Chan KL; Ng IO; Day PJ; Luk JM
J Proteome Res; 2010 Apr; 9(4):1923-30. PubMed ID: 20121168
[TBL] [Abstract][Full Text] [Related]
32. Determination of serum des-gamma-carboxy prothrombin levels in patients with small-sized hepatocellular carcinoma: comparison of the conventional enzyme immunoassay and two modified methods.
Nomura F; Ishijima M; Horikoshi A; Nakai T; Ohnishi K
Am J Gastroenterol; 1996 Jul; 91(7):1380-3. PubMed ID: 8677999
[TBL] [Abstract][Full Text] [Related]
33. Transforming growth factor beta1 and soluble Fas serum levels in hepatocellular carcinoma.
Sacco R; Leuci D; Tortorella C; Fiore G; Marinosci F; Schiraldi O; Antonaci S
Cytokine; 2000 Jun; 12(6):811-4. PubMed ID: 10843770
[TBL] [Abstract][Full Text] [Related]
34. Plasma proteasome level is a reliable early marker of malignant transformation of liver cirrhosis.
Henry L; Lavabre-Bertrand T; Vercambre L; Ramos J; Carillo S; Guiraud I; Pouderoux P; Bismuth M; Valats JC; Demattei C; Duny Y; Chaze I; Funakoshi N; Bureau JP; Daurès JP; Blanc P
Gut; 2009 Jun; 58(6):833-8. PubMed ID: 19201777
[TBL] [Abstract][Full Text] [Related]
35. Clinical significance of simultaneous determinations of alpha-fetoprotein and des-gamma-carboxy prothrombin in monitoring recurrence in patients with hepatocellular carcinoma.
Aoyagi Y; Oguro M; Yanagi M; Mita Y; Suda T; Suzuki Y; Hata K; Ichii K; Asakura H
Cancer; 1996 May; 77(9):1781-6. PubMed ID: 8646674
[TBL] [Abstract][Full Text] [Related]
36. Diagnostic and prognostic role of alpha-fetoprotein in hepatocellular carcinoma: both or neither?
Farinati F; Marino D; De Giorgio M; Baldan A; Cantarini M; Cursaro C; Rapaccini G; Del Poggio P; Di Nolfo MA; Benvegnù L; Zoli M; Borzio F; Bernardi M; Trevisani F
Am J Gastroenterol; 2006 Mar; 101(3):524-32. PubMed ID: 16542289
[TBL] [Abstract][Full Text] [Related]
37. Cytokine evaluation in liver cirrhosis and hepatocellular carcinoma.
Cheng KS; Tang HL; Chou FT; Chou JW; Hsu CH; Yu CJ; Kao ST; Li TC
Hepatogastroenterology; 2009; 56(93):1105-10. PubMed ID: 19760951
[TBL] [Abstract][Full Text] [Related]
38. Surface enhanced laser desorption/ionization profiling: New diagnostic method of HBV-related hepatocellular carcinoma.
Wu C; Wang Z; Liu L; Zhao P; Wang W; Yao D; Shi B; Lu J; Liao P; Yang Y; Zhu L
J Gastroenterol Hepatol; 2009 Jan; 24(1):55-62. PubMed ID: 18823443
[TBL] [Abstract][Full Text] [Related]
39. Usefulness of simultaneous determination of alpha-fetoprotein and des-gamma-carboxy prothrombin in hepatocellular carcinoma.
Nakao A; Taniguchi K; Inoue S; Harada A; Nonami T; Watanabe K; Takagi H
Semin Surg Oncol; 1996; 12(3):160-3. PubMed ID: 8727604
[TBL] [Abstract][Full Text] [Related]
40. Sensitive measurement of serum abnormal prothrombin (PIVKA-II) as a marker of hepatocellular carcinoma.
Tanaka Y; Kashiwagi T; Tsutsumi H; Nagasawa M; Toyama T; Ozaki S; Naito M; Ishibashi K; Azuma M
Hepatogastroenterology; 1999; 46(28):2464-8. PubMed ID: 10522021
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
